Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) Invested Capital (2020 - 2025)

Bioventus' Invested Capital history spans 6 years, with the latest figure at $478.1 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 1.14% year-over-year to $478.1 million; the TTM value through Dec 2025 reached $478.1 million, down 1.14%, while the annual FY2025 figure was $478.1 million, 1.14% down from the prior year.
  • Invested Capital reached $478.1 million in Q4 2025 per BVS's latest filing, down from $497.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $965.3 million in Q4 2021 to a low of $232.6 million in Q3 2021.
  • Average Invested Capital over 5 years is $527.1 million, with a median of $546.5 million recorded in 2024.
  • Peak YoY movement for Invested Capital: surged 506.52% in 2021, then plummeted 54.13% in 2023.
  • A 5-year view of Invested Capital shows it stood at $965.3 million in 2021, then dropped by 14.14% to $828.8 million in 2022, then dropped by 27.49% to $601.0 million in 2023, then decreased by 19.53% to $483.6 million in 2024, then dropped by 1.14% to $478.1 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Invested Capital are $478.1 million (Q4 2025), $497.1 million (Q3 2025), and $537.5 million (Q2 2025).